Nutriband Inc. (NTRBW) 株式分析

企業概要

Nutriband Inc. is a specialized developer focused on creating a portfolio of transdermal pharmaceutical products within the United States market. Although specific sector and industry classifications are not disclosed in current public filings, the company's operational focus remains on extended-release delivery systems for pharmaceutical compounds. The entity reports a trailing twelve-month revenue of $2.28M, which positions it as a micro-cap enterprise with limited scale compared to established pharmaceutical peers. This modest revenue figure, combined with a lack of disclosed market capitalization and employee count, indicates that the company is in a developmental phase where market penetration and commercialization are primary drivers rather than established market share. The absence of detailed industry categorization suggests the firm operates in a niche segment of the healthcare industry, relying heavily on the successful development and regulatory approval of its lead assets, specifically AVERSA fentanyl, to achieve meaningful commercial traction in the future.

財務健全性

The company's financial statements for the trailing twelve months reveal a revenue of $2.28M, while net income stands at -$34,592,176 and EBITDA is -$9,029,840. The substantial gap between the modest revenue of $2.28M and the significant net loss of approximately $34.6 million highlights an aggressive cost structure or heavy investment in research and development expenses that far outpace current sales. Free cash flow is reported at -$2,588,350, indicating that the company is currently burning cash to fund its operations and product development initiatives rather than generating liquidity from its business activities. The gross margin stands at 33.5%, which suggests a favorable pricing power or high-value product mix at the cost of goods sold level, whereas the operating margin of -1121.3% reflects severe operational inefficiencies or high fixed costs relative to revenue. Furthermore, the profit margin is listed at 0.0%, a figure that, when juxtaposed with the large net loss, points to significant non-operating expenses or unusual accounting adjustments impacting the bottom line. On the balance sheet, the company holds $5.31M in cash against $258,025 in debt, resulting in a debt-to-equity ratio of 3.42. Despite the high leverage ratio, the substantial cash reserve provides a significant buffer against the existing debt obligations. The current ratio of 7.53 indicates a robust short-term liquidity position, as the company possesses ample current assets to cover its current liabilities many times over. However, the return on equity of -136.1% and return on assets of -55.2% demonstrate that the company is currently destroying shareholder value and utilizing its assets inefficiently to generate profit.

バリュエーション評価

Trailing P/E and forward P/E ratios are not available for Nutriband Inc. due to the company's net loss position, which precludes the calculation of traditional earnings-based valuation multiples. Consequently, the price-to-book ratio of 1.85 becomes the primary metric for assessing value, indicating that the market is pricing the company at a premium of roughly 85% over its net book value. The absence of a price-to-sales ratio and EV/EBITDA multiples further underscores the reliance on asset-based valuation for this loss-making entity. Regarding trading levels, the 52-week high is $4.50 and the 52-week low is $0.80. Without a specific current share price provided in the available facts to calculate the exact percentage, the stock trades within this established volatility range, reflecting the high-risk nature of early-stage biopharma investments. The beta value of 1.93 signifies that the stock is highly volatile and tends to fluctuate with significantly greater magnitude than the broader market, amplifying both potential gains and losses during periods of market movement. Investors must recognize that valuation in this context is driven more by asset liquidity and potential product pipeline value than by traditional earnings multiples.

Growth & Income

Revenue growth year-over-year is recorded at -46.4%, indicating a contraction in sales performance, while earnings growth is not applicable (N/A) due to the company's continued losses. The decline in revenue suggests challenges in commercializing the current product portfolio or a reduction in demand for the transdermal fentanyl systems. Since the company reports no dividend yield and no payout ratio, it does not distribute income to shareholders, implying that any retained earnings or cash reserves are intended to be reinvested into research, development, and operational scaling. The lack of a sustainable dividend program is consistent with the company's financial profile, where capital is prioritized for product advancement rather than income distribution. Overall, the growth and income profile of Nutriband Inc. is characterized by significant revenue contraction, negative earnings, and a complete absence of dividend income, reflecting a high-risk, high-volatility investment characteristic of companies in the early stages of pharmaceutical development.